Table 4 Characteristics of patients according to HHV-6 positivity in bile. Comparison of patients based on the main primary outcome parameter of retransplantation-free survival. Data is given as mean (± SD), median (range) or number (%), as appropriate
|  | HHV-6 negative, n = 48 (65.7%) | HHV-6 positive, n = 25 (34.2%) | p |
|---|---|---|---|
Gender, female (%) | 8/48 (16.7%) | 7/25 (28.0%) | 0.20 |
Recipient Age (median, range), years | 55 (30–69) | 59 (41–66) | 0.36 |
Follow up (median, range), months | 39.5 (2.0–91.2) | 20.7 (0.6–102.9) | 0.78 |
Time of ERC (median, range), months | 3.5 (0.3–73.6) | 2.4 (0.3–22.1) | 0.38 |
Donor age (median, range), years | 60 (21–88) | 61 (27–82) | 0.65 |
eMELD at LT, points (mean ± SD) | 27.6 (± 5.3) | 27.3 (± 4.9) | 0.87 |
labMELD at LT, points (mean ± SD) | 16.4 (± 9.5) | 22.5 (± 12.2) | 0.02 |
Cold ischemia time,hours, (mean ± SD) | 9.8 (± 2.6) | 10.4 (± 2.7) | 0.37 |
AS | 25/48 (48.1%) | 9/25 (36.0%) | 0.17 |
NAS | 20/48 (41.7%) | 17/25 (68.0%) | 0.03 |
Acute rejection | 8/48 (16.6%) | 11/25 (44.0%) | 0.01 |
CMV positivity in bile | 10/48 (20.8%) | 3/23 (13.0%) | 0.33 |
HHV-7 positivity in bile | 6/48 (12.5%) | 9/25 (36.0%) | 0.02 |
HHV-6 positivity in liver biopsy | 4/33 (12.1%) | 4/20 (20.0%) | 0.30 |
HHV-6 positivity in serum | 0/30 (0%) | 1/11 (9.1%) | 0.29 |
AP (U/ml, SD) | 194.1 (± 125.4) | 195.6 (± 153.8) | 0.96 |
Bilirubin (mg/ml, SD) | 6.2 (± 9.3) | 7.6 (± 8.8) | 0.52 |
AST (U/ml, SD) | 100.9 (± 102.9) | 144.9 (± 192.5) | 0.21 |
Leukocytes (cells/nl, SD) | 6.2 (± 2.7) | 7.7 (± 5.5) | 0.12 |